Diaceutics
DXRX.LPrivate Company
Total funding raised: $45.5M
Overview
Diaceutics' mission is to ensure every patient receives the right therapy at the right time by solving the commercialization challenges of precision medicine. The company has evolved from a consultancy into a data and analytics-driven platform leader, serving over 20 of the world's top pharmaceutical companies and hundreds of therapy programs. Its core strategy revolves around its DXRX platform, which aggregates global lab data and applies AI to generate actionable insights, enabling pharmaceutical clients to optimize testing rates, physician education, and ultimately, therapy adoption.
Technology Platform
DXRX - The Diagnostic Network®, the world's first diagnostic commercialization platform. It integrates real-world diagnostic data from a global laboratory network and uses AI/ML analytics to power engagement modules like DXRX Signal, Physician Engage, and Expert Exchange.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Competes with large CROs/consultancies (e.g., IQVIA) offering broad services, real-world data firms (e.g., Flatiron, Tempus) focused on clinical outcomes, and specialist diagnostic consultancies. Diaceutics differentiates through its first-mover DXRX platform, proprietary global diagnostic dataset, and unique closed-loop model integrating data, AI insights, and direct physician engagement tools.
Company Timeline
Founded in Belfast, United Kingdom
Series A: $5.5M
IPO — $25.0M
Series B: $15.0M